Emerging stroke literature suggests that treatment of experimentally induced stroke with stem cells offered post-stroke neuroprotection via exosomes produced by these cells. Treatment with exosomes has great potential to overcome the limita- tions associated with cell-based therapies.
Stem cell treatment is one of the potential treatment options for ischemic stroke. We recently demonstrated a protective effect of human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) in a rat model of ischemic stroke.
Evidence suggests that apoptosis contributes significantly to cell death after cerebral ischemia. Our recent studies that utilized human umbilical cord blood- derived mesenchymal stem cells (hUCBSCs) demonstrated the potential of hUCBSCs to inhibit neuronal apoptosis in a rat model of CNS injury.
Several clinical studies report increased patient survival following the intravenous infusion of mesenchymal stem cells (MSCs) during the past year. MSCs block the cytokine storm in the lungs and also regenerate cells and tissues damaged by the COVID-19 virus. MSCs are not vaccines and work differently in the treatment of COVID-19.
Bone marrow stem cell therapies, based on transplant of hematopoietic stem cells (HSCs) have been used for over 50 years in the treatment of blood disorders including leukemia, lymphoma, and auto-immune disorders. Embryonic stem cells (ESCs) were discovered in the late 1990’s by Evans, Kauffman, and Martin. J Thompson developed procedures to isolate and expand ESCs from human embryos. Since ESCs could differentiate into any cell in the body, this expanded application of stem therapy to include broad areas in disease treatment and regenerative medicine.
Multipotent mesenchymal stromal/stem cells (MSCs) have the potential to repair and regenerate damaged tissues, making them attractive candidates for cell-based therapies. Expanded and well-characterized MSCs have application in regenerative medicine and have been used in several clinical trials including osteoarthritis and other conditions,
Mesenchymal stromal/stem cells (MSCs) have the potential to repair and regenerate damaged tissues, making them attractive candidates for cell-based therapies. Expanded and well-characterized MSCs have application in regenerative medicine and have been used in several clinical trials including treatment for osteoarthritis and other conditions.
Recently the FDA issued permanent injunctions against stem cell clinics using a type of stem cell product called Stromal Vascular Fraction (SVF). This product (“The Bad”) is derived from fat retrieved from a patient by liposuction. It is then digested by enzymes, washed and filtered to yield SVF. It is injected back into the patient receiving the liposuction for various therapies.
As we age, our cells get sick and die. When a cell dies, it creates a cascade of events, leading to inflammation and disease that can decrease lifespan. Many environmental factors accelerate aging such as stress, pollution, lifestyle, injuries, disease, and exposure to toxins. A recently published study reviewed evidence that delaying and reversing aging in cells is feasible. Epigenetic changes drive aging and reversal of these changes extend lifespan1.